BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration
NCT ID: NCT04882956
Last Updated: 2021-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2020-08-05
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration
NCT04690062
Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD
NCT03744806
Beovu Experience UZ Leuven
NCT05220085
Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept
NCT04287348
Intravitreal Bevacizumab for Age-Related Macular Degeneration
NCT00347165
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BEOVU
Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
intravitreal injection
Brolucizumab-Dbll intravitreal injection
Eylea
Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months
intravitreal injection
Aflipercept intravitreal injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intravitreal injection
Brolucizumab-Dbll intravitreal injection
intravitreal injection
Aflipercept intravitreal injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* other macular diseases
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tarek Roshdy mohamed Mahgoub ELhamaky
Professor (associate)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tarek Elhamaky, MD
Role: PRINCIPAL_INVESTIGATOR
Benha University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
INMC
Abu Dhabi, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Tarek Elhamaky, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
TAREK R ELHAMAKY, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hamaky11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.